Core Viewpoint - Tevogen Bio emphasizes its commitment to preserving equity for shareholders while exploring financing strategies in the biotech sector, focusing on efficiency, asset ownership, and a path to revenue [1][2]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company that develops off-the-shelf, genetically unmodified precision T cell therapies targeting infectious diseases and cancers, addressing significant unmet needs in large patient populations [2]. - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents, with two related to artificial intelligence [2]. Leadership and Strategy - Tevogen Bio is led by a team of experienced industry leaders and scientists with expertise in drug development and global product launches, believing that accessible personalized therapeutics represent the next frontier of medicine [3]. - The company advocates for disruptive business models to sustain medical innovation and ensure patient accessibility through advanced science [3]. Financial Position - Tevogen Bio's assets are valued in the billions, although this value is not reflected on its balance sheet due to US GAAP restrictions on capitalizing internally developed intangible assets [5]. - The company's market cap per employee is approximately 600% higher than the industry average, indicating strong operational efficiency [5]. - Tevogen has a self-sustaining financing strategy, with multiple avenues to secure funds without selling equity, aiming for long-term sustainability [5]. Business Model - Tevogen's business model challenges traditional biotech financing norms, focusing on making advanced immunotherapies accessible and affordable [5]. - The company believes that its true value will become more recognized as awareness grows, and encourages employee ownership as a means to align interests [5].

Core Viewpoint - Tevogen Bio has successfully secured strategic financing and grant funding, reflecting confidence in its innovative business model and commitment to developing accessible, personalized T cell therapies for large patient populations [2][3][4]. Financing Activity - Tevogen Bio received $2 million from a grant agreement on January 28, 2025, with the potential for an additional $8 million based on future evaluations [2]. - The company signed a letter of intent on October 29 to establish a research and development facility valued at up to $50 million, which will not dilute existing shareholders [7]. - On August 15, 2024, Tevogen Bio completed a $6 million Series C Preferred Stock investment, featuring a 7.5% annual dividend and convertible into common stock after six months [7]. - A financing agreement was made on June 11 for up to $50 million, including a $36 million line of credit and a $14 million contingent private placement [7]. - An $8 million Series A Preferred Stock investment was secured on February 15, 2024, coinciding with the company's public debut [7]. Company Overview - Tevogen Bio specializes in developing off-the-shelf, genetically unmodified precision T cell therapies targeting infectious diseases, cancers, and neurological disorders [4]. - The company emphasizes sustainability and patient accessibility as key components of its business model, aiming to address significant unmet medical needs [4][5]. - Tevogen Bio has reported positive safety data from its proof-of-concept clinical trials, and it owns all key intellectual property assets without third-party licensing [4]. Leadership and Vision - The leadership team at Tevogen Bio consists of experienced industry leaders and scientists with a strong background in drug development and global product launches [5]. - The company believes that accessible personalized therapeutics represent the next frontier in medicine, necessitating disruptive business models to sustain innovation [5].

Core Viewpoint - Tevogen Bio emphasizes the importance of addressing the challenges posed by short-selling on healthcare innovation and its commitment to advancing affordable medical solutions while maintaining transparency and fairness in the market [2][3][4]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing precision T cell therapies using CD8+ cytotoxic T lymphocytes to treat infectious diseases and cancers, aiming to meet significant unmet medical needs [5]. - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and additional pending patents related to artificial intelligence [5]. Strategic Initiatives - Tevogen Bio has formed a collaboration with Microsoft to explore AI applications in biotechnology, which is part of its broader strategy to enhance its product pipeline and ensure patient accessibility [2][5]. - The leadership believes that sustainable healthcare innovation relies on advanced science and innovative business models to ensure patient access [5][6]. Market Position and Challenges - The company faces pressure on its share price despite its advancements, raising concerns about the impact of short-selling on its focus and priorities [2][3]. - Tevogen Bio's leadership advocates for fair market participation, emphasizing the need for transparency and fairness for retail investors [4].

WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, congratulates Robert F. Kennedy Jr.’s as he begins his role at the head of Health and Human Services. Secretary Kennedy and the administration’s collective goal of achieving accessibility to affordable healthcare in the U.S. aligns with Tevogen Bio’s business model, which focuses on delivering ...

Core Viewpoint - Tevogen Bio is positioned as a potential leader in the biopharma industry by focusing on cost-efficient, value-driven healthcare solutions amid increasing competition and regulatory changes [1][2] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy biotech company that develops off-the-shelf, genetically unmodified precision T cell therapies targeting infectious diseases and cancers [3][4] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents [3] Industry Context - The U.S. biotech sector is under pressure to adapt due to competition from Chinese pharmaceutical companies that develop drugs more quickly and at lower costs [2] - The appointment of Robert F. Kennedy Jr. as head of the Department of Health and Human Services has shifted focus towards affordable healthcare, prompting discussions on sustainability and access within the industry [2] Business Model and Strategy - Tevogen Bio's business model aims to deliver groundbreaking medical innovations while ensuring affordability and sustainability, addressing current industry concerns [3] - The leadership believes that accessible personalized therapeutics represent the next frontier of medicine, necessitating disruptive business models to sustain medical innovation [4]

Core Insights - Tevogen Bio is positioned as a potential leader in the biopharma industry by focusing on cost-efficient, value-driven healthcare solutions amid increasing competition and regulatory changes [1][2] - The company aims to redefine healthcare economics by delivering innovative medical solutions while ensuring affordability and sustainability [3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy biotech company that develops precision T cell therapies targeting infectious diseases and cancers [3] - The company utilizes CD8+ cytotoxic T lymphocytes, which are genetically unmodified, to address significant unmet medical needs [3] - Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and several pending patents related to artificial intelligence [3] Industry Context - The U.S. biotech sector is under pressure to adapt due to the rapid development and lower costs of drugs by Chinese pharmaceutical companies [2] - The appointment of Robert F. Kennedy Jr. as head of the Department of Health and Human Services emphasizes the need for affordable healthcare, prompting discussions on sustainability and access within the industry [2] Leadership and Vision - Tevogen Bio's leadership comprises experienced industry professionals who believe that accessible personalized therapeutics represent the next frontier in medicine [4] - The company is committed to innovative business models that support ongoing medical advancements and patient accessibility [4]

Core Insights - Tevogen Bio is a clinical-stage specialty immunotherapy biotech company focusing on affordable and scalable ExacTcell technology, which has shown positive results in its proof-of-concept clinical trial for TVGN 489 [1][3] - The company aims to address significant unmet needs in treating infectious diseases, cancers, and neurological disorders through precision T cell therapies [3][4] - Tevogen Bio's leadership emphasizes the importance of patient accessibility and innovative business models for sustainability and commercial success in healthcare [3][4] Company Overview - Tevogen Bio utilizes CD8+ cytotoxic T lymphocytes to develop off-the-shelf, genetically unmodified precision T cell therapies [3] - The company has reported positive safety data from its clinical trials and owns key intellectual property assets, including three granted patents and numerous pending patents related to artificial intelligence [3] - The leadership team consists of experienced industry leaders and scientists with expertise in drug development and global product launches [4] Strategic Initiatives - The company discussed ExacTcell's capability to rapidly adapt to emerging viral threats during a meeting with BARDA, positioning it as a potential public health countermeasure [2] - Tevogen Bio plans to follow up with key federal entities and keep stakeholders updated on its progress [2]

Core Insights - Tevogen Bio is advancing its ExacTcell technology, which has shown positive results in clinical trials and is designed to rapidly adapt to emerging viral threats, positioning it as a potential public health countermeasure [1][2]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, genetically unmodified precision T cell therapies targeting infectious diseases, cancers, and neurological disorders [3]. - The company emphasizes the importance of patient accessibility through advanced science and innovative business models to achieve sustainability and commercial success in healthcare [3]. - Tevogen Bio owns key intellectual property assets, including three granted patents and numerous pending patents, with a focus on artificial intelligence [3]. Leadership and Vision - The leadership team at Tevogen Bio consists of experienced industry leaders and distinguished scientists with expertise in drug development and global product launches [4]. - The company believes that accessible personalized therapeutics represent the next frontier in medicine and that disruptive business models are essential for sustaining medical innovation [4].

WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Patton on being appointed Deputy Assistant to the President and Director of Minority Outreach. Ms. Patton will join the Office of Public Liaison and will be responsible for ensuring that President Trump continues to build upon his Election Day support from Blacks, Latinos and W ...

WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Patton on being appointed Deputy Assistant to the President and Director of Minority Outreach. Ms. Patton will join the Office of Public Liaison and will be responsible for ensuring that President Trump continues to build upon his Election Day support from Blacks, Latinos and ...